Adagene Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ADAG Nasdaq 2836 www.adagene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adagene Inc.

Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025 - Jan 14th, 2025 1:00 pm
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Jan 8th, 2025 2:40 pm
Is Bioventus (BVS) Outperforming Other Medical Stocks This Year? - Dec 23rd, 2024 2:40 pm
Are Medical Stocks Lagging Adagene (ADAG) This Year? - Dec 6th, 2024 2:40 pm
November 2024's Top Picks: Penny Stocks On US Exchanges - Nov 29th, 2024 8:09 pm
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Nov 7th, 2024 3:01 pm
Adagene And 2 Other US Penny Stocks To Consider - Oct 21st, 2024 11:31 pm
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Oct 9th, 2024 10:00 am
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year? - Sep 27th, 2024 1:40 pm
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - Sep 16th, 2024 7:01 am
Adagene to Participate in Investor Conferences in September - Aug 29th, 2024 11:00 am
Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year? - Aug 9th, 2024 1:40 pm
Adagene First Half 2024 Earnings: US$0.39 loss per share (vs US$0.094 loss in 1H 2023) - Jul 28th, 2024 1:26 pm
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update - Jul 25th, 2024 8:05 pm
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September - Jul 12th, 2024 11:00 am
Adagene Inc. (NASDAQ:ADAG) most popular amongst private equity firms who own 39% of the shares, institutions hold 30% - Jun 20th, 2024 12:04 pm
Adagene to Present at Investor Conferences in June - May 22nd, 2024 8:45 pm
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update - Mar 29th, 2024 1:00 pm
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board - Mar 7th, 2024 9:01 pm
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 - Feb 27th, 2024 1:00 pm